Log in to save to my catalogue

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2471841028

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-fo...

Alternative Titles

Full title

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2471841028

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2471841028

Other Identifiers

ISSN

0028-0836

E-ISSN

1476-4687

DOI

10.1038/s41586-020-2814-7

How to access this item